Biosergen successfully completes first cohort of BSG005 phase I trial
May 13, 2022: Biosegen AB (“Biosergen” or the “Company”) today announced that the Safety Review Committee found no safety issues in the first 6-volunteer cohort in the Single Ascending Dose part of BSG005’s phase I trial. The trial will escalate to the next dose level as planned.
BSG005 is Biosergen’s lead development compound. It is an anti-fungal molecule from the group of polyene macrolides known for their broad anti-fungal and fungicidal effect, including on resistant and difficult-to-treat fungal strains.
The clinical phase I trial is a double-blinded, placebo-controlled study in up to 72 healthy male volunteers (subjects). The trial is designed as a Single Ascending Dose (SAD) study followed by a Multiple Ascending Dose (MAD) study to investigate the safety and tolerability of BSG005. It is conducted in the Nucleus Network phase I Unit in Melbourne, Australia.
Biosergen’s CEO Peder M. Andersen comments:
“We are off to a good start. If this trial continuous to show that BSG005 is well tolerated and that we can achieve what we believe are thereapeutic concentrations of the drug in the bloodstream of the subjects at safe doses, Biosergen will have taken a very significant step forward. I look forward to keeping you updated as the results come in.”
Phase I study design
The phase I study is divided into two sequential parts:
- The Single Ascending Dose (SAD) part of the trial will enrol up to 42 subjects divided into 7 groups of 6 subjects each. In each cohort, 4 subjects receive a single dose of BSG005, whereas 2 receive placebo. Each subject participates in just one treatment cohort, and no subject receives more than one dose of BSG005 (or placebo as the case may be). The dose of BSG005 will be increased for each progressive group if previous dose levels are well tolerated and no safety issues observed. These safety reviews are performed by the study’s Safety Review Committee after each dose level.
The Multiple Ascending Dose (MAD) part of the trial will enroll up to 30 subjects divided into 5 groups of 6 subjects each. In this part of the trial, the subjects receive increasing doses of BSG005 over a 7 day period. While the objectives of the Single Ascending Dose trial above is to establish a basic understanding of BSG005’s pharmacokinetics and maximum tolerated dose when given as a single dose, the Multiple Ascending Dose part of the trial aims to establish what dose level of BSG005 is required to obtain a steady, clinically relevant concentration of the drug in the subject’s blood stream. Biosergen expects to be able to publish data from this part of the trial in Q4 2022.
For further information about Biosergen, please contact:
Dr. Peder M. Andersen, CEO
Telephone: +45 2080 2470
E-mail: [email protected]
Erik Penser Bank
Telefon: +46 8 463 8000
E-mail: [email protected]
This information is such information that Biosergen AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on May 13, 2022.
Biosergen is a clinical stage biotechnology company that employs the majority of its organisational and financials resources on the clinical development of BSG005. BSG005 is a potentially disruptive antifungal drug with blockbuster potential based on significant safety and potency advantages over competing antifungals, including Amphotericin B, in more than a decade of preclinical studies. The research behind BSG005 and its unique properties has been documented in over 20 peer reviewed scientific papers. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS-, cancer- and transplant patients every year. At equal dose levels BSG005 shows a three-to-fourfold potency advantage against relevant fungal strains compared to current standards of care, while being completely free of the kidney toxicity hampering other drugs in its class. The Company is also developing BSG005 Nano where the drug is packed in special nano particles to specifically target the lung, often the first affected organ in an invasive fungal infection. BSG005 Nano Oral is an extension of BSG005 Nano. An oral formulation would greatly increase the usefulness, particularly as a prophylactic and as home treatment after transplants or cancer treatment to prevent invasive fungal infection. Biosergen has received orphan drug status for BSG005 in the United States.
RLS Global: Emissionen registrerad och handeln med BTA upphör
RLS Global AB (publ) (”RLS Global” eller ”Bolaget”) har genomfört en företrädesemission av aktier som avslutades den 11 november 2022. Företrädesemissionen är nu registrerad vid Bolagsverket och sista dag för handel med betald tecknad aktie (”BTA”) är onsdag den 14 december 2022. Avstämningsdag är 1...
RLS Global: The rights issue is registered and the trading in Paid Subscription Shares ceases
RLS Global AB (publ) (”RLS Global” or "the Company”) has completed a rights issue of shares that closed on 11 November, 2022. The rights issue is now registered with the Swedish Companies Registration Office and the last day for trading in paid subscribed shares ("BTA") will be Wednesday, December 1...
Nexstim Receives an NBS System Order from a Hospital in Poland
This is Nexstim’s first sale to Poland. The system will be used for performing neurosurgery planning in patients that have had a diagnosis of a brain tumor or other disorder. The Nexstim NBS System is the only FDA cleared and CE-marked navigated TMS system for pre-operative mapping of the motor and...
Diagonal Bio AB tillkännager initial detektionsgräns (LoD) för Panviral i linje med PCR standard
Diagonal presenterar idag nya testresultat för Panviral-systemets LoD för detektion av syntetisk influensa RNA. Testet utfördes med den senaste versionen av Panviral ämnad för forskningsändamål (Instrument for Research Use Only, RUO) samt Cartridge och ReactionMix...